<DOC>
	<DOCNO>NCT02929693</DOCNO>
	<brief_summary>The investigator perform multi-centered , randomize , double blind , placebo-controlled , prospective clinical trial effect Yiqi-yangyin-jiedu decoction ( YYJD ) , chinese herbal medicine ( CHM ) formula combine gefitinib prolong progression free survival ( PFS ) advance pulmonary adenocarcinoma patient activate EGFR mutation ( exon19del exon21L858R ) . The investigator plan enroll 198 case 3 year ( 99 case gefitinib , 99 case gefitinib plus YYJD ) , expect combination therapy well efficacy prolong PFS , overall survival , improve quality life ( QOL ) .</brief_summary>
	<brief_title>Clinical Study YYJD Decoction Combined With Gefitinib Advanced Pulmonary Adenocarcinoma</brief_title>
	<detailed_description>Non-Small-Cell Lung Cancer（NSCLC）is one malignancies high incidence mortality . Epidermal growth factor receptor ( EGFR ) implicate NSCLC pathogenesis . Certain patient subgroup NSCLC ( ie , woman , never-smokers , East Asians , adenocarcinoma ) high rate EGFR mutation , render responsive EGFR tyrosine kinase inhibitor ( TKIs ; eg , gefitinib , erlotinib , Icotinib ) . Among patient advance EGFR-mutated NSCLC , treatment EGFR-TKIs associate response rate 56 74 % median progression-free survival ( mPFS ) 10 14 month ; outcomes superior platinum-based chemotherapy . Despite initial response EGFR-TKIs , majority patient disease progression within 1 2 year treatment initiation ( acquire resistance ) . In approximately 60 % patient , mechanism acquire resistance development additional EGFR mutation , EGFR T790M . Although AZD9291 ( AstraZeneca ) , third-generation EGFR-TKI report response rate 61 % NSCLC patient EGFR T790M mPFS 9.6 month , resistance third-generation inhibitor mediate EGFR C797S mutation inevitable . Therefore , optimize effect generation EGFR-TKI essential long-term survival NSCLC.The investigator ' preliminary study show combine Yiqi-yangyin-jiedu decoction ( YYJD ) gefitinib prolong PFS improve QOL , high-level evidence need . The investigator perform multi-centered , randomize , double blind , placebo-controlled , prospective clinical trial effect YYJD , chinese herbal medicine ( CHM ) formula combine gefitinib advance pulmonary adenocarcinoma patient activate EGFR mutation ( exon19del exon21L858R ) choose gefitinib first-line second line therapy . Patients randomize observational group ( YYJD plus gefitinib ) , control group ( placebo plus gefitinib ) . The treatment continue evidence disease progression unacceptable toxicity , regular follow-up arrange . The primary efficacy assessment : PFS ( progression-free survival ) ; Secondary efficacy assessment : ( 1 ) OS ( overall survival ) ; ( 2 ) Objective response rate ; ( 3 ) QOL ( Functional Assessment Cancer therapy-lung , FACT-L4.0 scale ; Lung Cancer Symptom Scale , LCSS ) ; ( 4 ) efficacy assessment : 1 ) TCM symptom change ; 2 ) Toxicity , side effect security treatment assess time . The investigator plan enroll 198 case 3 year ( 99 case gefitinib , 99 case gefitinib plus YYJD ) , expect combination therapy well efficacy prolong PFS , overall survival , improve quality life ( QOL ) . Therefore study provide evidence optimize promote efficacy gefitinib .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Pathologically cytologically confirm stage IIIaIV pulmonary adenocarcinoma ; With activate EGFR mutation ( either exon19del exon21L858R ) one month gefitinib firstline secondline therapy without disease progression ( PD ) ; With TCM diagnostic pattern Qinandyin dificiency ; Age ≥18 year old ; Estimated life expectancy least 12 week ; Without major organ dysfunction : hemoglobin ≥9 g/dL , absolute neutrophil count ( ANC ) ≥1.5*109/L , platelet ≥100 *109/L , bilirubin ≤1.5ULN , alkaline phosphatase ( AP ) , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤2.5 upper limited number ( ULN ) ( AP , AST , ALT ≤5ULN acceptable liver metastasis ) .INR≤1.5 , APTT normal range ( 1.2DLN1.2ULN ) , creatinine ≤1.5ULN ; malignant tumor except NSCLC 5 year previous study entry ; PD onee month gefitinib treatment Estimated life expectancy le 12 week ; Brain metastasis relevant symptom History cardiovascular disease : Congestive Heart Failure &gt; grade II NYHA.Unstable angina patient ( angina symptom rest ) new occurrence angina ( begin last 3 month ) myocardial infarction happen last 6 month ; Pregnant child breast feeding woman ; Mental cognitive disorder ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>